Relay Therapeutics(NASDAQ) RLAY

Relay Therapeutics develops new medicines for cancer patients. Its scientists study how proteins move to design better drugs. These therapies target specific genetic conditions in the body.

Developing Targeted Cancer Therapies

• Zovegalisib: Lead drug candidate targeting breast cancer and vascular anomalies; currently in Phase 3 clinical trials.
• RLY-4008: Oral treatment for solid tumors with specific changes to the fibroblast growth factor receptor 2 protein.
• RLY-1971: Drug candidate designed to block Src homology region 2 domain-containing phosphatase-2, a protein involved in tumor growth.
• RLY-8161: Clinical-stage candidate for melanoma and other tumors with specific genetic mutations.

Strategic Milestones and Partnerships

• Entered a global licensing agreement with Elevar Therapeutics for lirafugratinib in December 2024.
• Raised $296.8 million in net proceeds through a public stock offering in May 2026.
• Selected a Pfizer investigative drug as a clinical trial partner for combination therapies in April 2026.
• Secured $159.2 million in net proceeds from at-the-market stock sales by June 30, 2026.

Innovation Through Protein Motion

The Dynamo platform uses computational and experimental methods to drug targets once considered unreachable. This approach focuses on protein motion to find new ways to treat cancer and genetic diseases.

Financial Results and Funding

• Market capitalization reached $3.8 billion in Q2 2026, up 540.5% year over year.
• Net loss was $157.0 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and investments totaled $910.9 million as of June 30, 2026.
• Research and development expenses were $147.0 million for the half-year period ended June 30, 2026.

The Bottom Line

Relay has transitioned from an early-stage research company to a clinical-stage organization with multiple programs in human trials. Its focus on computational drug discovery and strategic alliances supports its long-term development of precision medicines.